Interested parties may access the live webcast of the presentation by visiting the Investors & Media section of the Cytokinetics website at https://www.cytokinetics.com. The webcast replay will be ...
Cytokinetics is advancing aficamten, a potential competitor to Camzyos, targeting hypertrophic cardiomyopathy. Read my CYTK ...
HC Wainwright reaffirmed their buy rating on shares of Cytokinetics (NASDAQ:CYTK – Free Report) in a research report sent to ...
Bank of America Securities analyst Jason Zemansky maintained a Hold rating on Cytokinetics (CYTK – Research Report) today and set a price ...
Cytokinetics' hopes of resurrecting cardiac myosin activator omecamtiv mecarbil have suffered another setback, after the drug failed to show a benefit in a phase 3 heart failure study.
Cytokinetics (NASDAQ:CYTK) said EU regulators have validated the market application for its drug aficamten for the treatment ...
That morning, Cytokinetics announced that Sanofi has acquired the Greater China development and commercialization rights to aficamten from Chinese healthcare company Corxel. This is a drug ...
Shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the sixteen brokerages that are presently covering the company, ...
Cytokinetics, Incorporated announced the granting of stock options and restricted stock units (RSUs) to nine new employees on December 31, 2024, as part of their employment inducement. The company ...
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 31, 2024 it granted stock options to purchase an aggregate ...
The stock options, RSUs and PSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635 (c) (4).